Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Posted
Alimera Sciences, Inc is a drug manufacturers-specialty & generic business based in the US. Alimera Sciences shares (ALIM) are listed on the NASDAQ and all prices are listed in US Dollars. Alimera Sciences employs 122 staff and has a trailing 12-month revenue of around USD$50.8 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$2.8602 - USD$10.79 |
---|---|
50-day moving average | USD$7.8415 |
200-day moving average | USD$5.6487 |
Wall St. target price | USD$14.25 |
PE ratio | 1.1297 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$0.303 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Alimera Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alimera Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Alimera Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Alimera Sciences shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Alimera Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$2.2 million.
The EBITDA is a measure of a Alimera Sciences's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | USD$50.8 million |
---|---|
Gross profit TTM | USD$43.9 million |
Return on assets TTM | -0.62% |
Return on equity TTM | 0% |
Profit margin | -10.51% |
Book value | $-0.479 |
Market capitalisation | USD$49 million |
TTM: trailing 12 months
There are currently 138,171 Alimera Sciences shares held short by investors – that's known as Alimera Sciences's "short interest". This figure is 1320.5% up from 9,727 last month.
There are a few different ways that this level of interest in shorting Alimera Sciences shares can be evaluated.
Alimera Sciences's "short interest ratio" (SIR) is the quantity of Alimera Sciences shares currently shorted divided by the average quantity of Alimera Sciences shares traded daily (recently around 121202.63157895). Alimera Sciences's SIR currently stands at 1.14. In other words for every 100,000 Alimera Sciences shares traded daily on the market, roughly 1140 shares are currently held short.
However Alimera Sciences's short interest can also be evaluated against the total number of Alimera Sciences shares, or, against the total number of tradable Alimera Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alimera Sciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Alimera Sciences shares in existence, roughly 20 shares are currently held short) or 0.0268% of the tradable shares (for every 100,000 tradable Alimera Sciences shares, roughly 27 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alimera Sciences.
Find out more about how you can short Alimera Sciences stock.
We're not expecting Alimera Sciences to pay a dividend over the next 12 months.
Alimera Sciences's shares were split on a 1:15 basis on 15 November 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alimera Sciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Alimera Sciences shares which in turn could have impacted Alimera Sciences's share price.
Over the last 12 months, Alimera Sciences's shares have ranged in value from as little as $2.8602 up to $10.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alimera Sciences's is 1.6387. This would suggest that Alimera Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. The company sells its products through direct sales and distributors to physician offices, pharmacies, and hospitals. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was founded in 2003 and is headquartered in Alpharetta, Georgia.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.